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Abstract
IMPORTANCE Evidence is lacking for viable treatment options for patients with difficult-to-treat
obsessive-compulsive disorder (OCD). It has been suggested that D-cycloserine (DCS) could
potentiate the effect of exposure and response prevention (ERP) treatment, but the hypothesis has
not been tested among patients with difficult-to-treat OCD.
OBJECTIVE To evaluate whether DCS potentiates the effect of concentrated ERP among patients
with difficult-to-treat OCD.
DESIGN, SETTING, AND PARTICIPANTS The study was a randomized placebo-controlled triple-
masked study with a 12-month follow-up. Participants were adult outpatients with difficult-to-treat
OCD. A total of 220 potential participants were referred, of whom 36 did not meet inclusion criteria
and 21 declined to participate. Patients had either relapsed after (n = 100) or not responded to
(n = 63) previous ERP treatment. A total of 9 specialized OCD teams within the public health care
system in Norway participated, giving national coverage. An expert team of therapists from the
coordinating site delivered treatment. Inclusion of patients started in January 2016 and ended in
August 2017. Data analysis was conducted February to September 2019.
INTERVENTIONS All patients received individual, concentrated ERP treatment delivered during 4
consecutive days in a group setting (the Bergen 4-day treatment format) combined with 100 mg
DCS, 250 mg DCS, or placebo.
MAIN OUTCOMES AND MEASURES Change in symptoms of OCD and change in diagnostic status.
Secondary outcomes measures included self-reported symptoms of OCD, anxiety, depression, and
quality of life.
RESULTS The total sample of 163 patients had a mean (SD) age of 34.5 (10.9) years, and most were
women (117 [71.8%]). They had experienced OCD for a mean (SD) of 16.2 (10.2) years. A total of 65
patients (39.9%) were randomized to receive 100 mg DCS, 67 (41.1%) to 250 mg of DCS, and 31
(19.0%) to placebo. Overall, 91 (56.5%) achieved remission at posttreatment, while 70 (47.9%) did
so at the 12-month follow-up. There was no significant difference in remission rates among groups.
There was a significant reduction in symptoms at 12 months, and within-group effect sizes ranged
from 3.01 (95% CI, 2.38-3.63) for the group receiving 250 mg DCS to 3.49 (95% CI, 2.78-4.18) for the
group receiving 100 mg DCS (all P < .001). However, there was no significant effect of treatment
group compared with placebo in obsessive-compulsive symptoms (250 mg group at posttreatment:
d = 0.33; 95% CI, −0.10 to 0.76; 100 mg group at posttreatment: d = 0.36; 95% CI, −0.08 to 0.79),




potentiate the effect of concentrated
exposure and response prevention in
difficult-to-treat obsessive-compulsive
disorder?
Findings In this randomized clinical trial
of 163 participants, D-cycloserine did
not significantly affect treatment
outcomes. Most patients responded to
the concentrated exposure and
response prevention treatment, and
nearly 50% were recovered at 1-year
follow-up.
Meaning In this study, concentrated
exposure and response prevention
treatment was effective for patients
with difficult-to-treat obsessive-
compulsive disorder, but adding
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Abstract (continued)
group at 12-month follow-up: d = 0.30; 95% CI, −0.17 to 0.76; Generalized Anxiety Disorder–7 score
among 100 mg group at 12-month follow-up: d = 0.27; 95% CI, −0.19 to 0.73), and well-being (250
mg group: d = 0.10; 95% CI, −0.42 to 0.63; 100 mg group: d = 0.34; 95% CI, −0.19 to 0.86). No
serious adverse effects were reported.
CONCLUSIONS AND RELEVANCE In this study, DCS did not potentiate ERP treatment effect, but
concentrated ERP treatment was associated with improvement.
TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02656342
JAMA Network Open. 2020;3(8):e2013249. doi:10.1001/jamanetworkopen.2020.13249
Introduction
Obsessive-compulsive disorder (OCD) is a debilitating psychiatric disorder with a lifetime prevalence
of 1% to 2%,1,2 often with onset in childhood.3 Exposure and response prevention (ERP) and
antidepressants are effective treatments,4,5 but response is mixed, indicating a need to develop
more effective strategies. Based on experimental animal studies demonstrating that D-cycloserine
(DCS), a partial N-methyl-D-aspartate receptor agonist,6,7 facilitates extinction learning, a number of
human clinical trials have assessed whether ERP is augmented by DCS. While some early publications
were promising,8,9 more recent meta-analyses show only small augmentation of DCS vs placebo
(effect size, 0.25)10 and others no significant difference,11-13 including no significant difference in
several studies involving patients with OCD.10,11,14-16 A study by Andersson et al17 concluded that DCS
did not augment the effects of cognitive behavioral therapy, but found that antidepressants may
interact with DCS to block its facilitating effect on fear extinction.
The DCS studies included in meta-analyses are based on samples in which a treatment response
would be expected for 62% to 68% of the sample.4 Potentiation by DCS may be more evident in
patients who have a documented history of being difficult to treat, ie, those who have not responded
to ERP or who have responded but then relapsed. These patients also constitute the group most in
need of alternative treatment approaches. One study18 reported that DCS accelerated the rate of
recovery in children with difficult-to-treat OCD, suggesting that DCS might also be helpful for adults
with difficult-to-treat OCD.
The present study targets patients with OCD who have a documented history of nonresponse
to or relapse following ERP treatment and investigates whether DCS potentiates the effect of
concentrated ERP treatment immediately after treatment and at 12-month follow-up. We
hypothesized that patients receiving DCS would demonstrate significantly greater reductions in OCD
symptoms relative to participants in the placebo group.
Methods
Norwegian health authorities have established 15 specialized adult OCD teams, yielding national
coverage. Nine teams recruited participants for the study. Data collection, management, training of
therapists, and organization of treatment were conducted from the Bergen site. Details regarding the
clinical training procedure are described elsewhere.19,20 A total of 8 group leaders and 64 therapists
participated. The study was approved by the regional committees for medical and health research
ethics in Norway, and all participants provided written consent. The trial protocol is available in
Supplement 1. The study followed the Consolidated Standards of Reporting Trials (CONSORT) guideline.
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Design and Participants
All patients received concentrated ERP treatment delivered during 4 consecutive days in groups of 3
to 6 patients with a 1:1 ratio between patients and therapists. The 2 middle days were used for
exposure treatment (eFigure 1 in Supplement 2). Effectiveness studies in routine clinical care19-22 as
well as a randomized clinical trial23 have demonstrated that 90% of patients with OCD respond to
ERP treatment delivered in this format and that 70% are recovered at 4-year follow-up,24 based on
the international consensus criteria.25
DCS was administered both days of exposure treatment. Given that research on optimal dosage
has been inconclusive,10,13 100 mg and 250 mg dosages were evaluated. Participants were stratified
by use of antidepressants.17 Thus, the study used a triple-masked, 3-group, placebo-controlled
design, in which patients within each stratum were randomized to 100 mg DCS, 250 mg DCS, or
placebo in a 2:2:1 ratio for an intended sample of 160. Randomization in blocks of 5 was done using an
online tool before the first patient was included in the study and concealed from all patients,
therapists, and independent assessors. Due to the group treatment format, the actual sample size
was 67 of 163 (41.1%) in the 250 mg group, 65 (39.9%) in the 100 mg group, and 31 (19.0%) in the
placebo group. The trial was announced through media and on the websites of the Norwegian OCD
association and the OCD teams. Inclusion lasted from January 2016 to August 2017.
Inclusion Criteria
We included patients who met Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition)
(DSM-5) criteria for OCD; were able to be treated as outpatients; were aged at least 18 years; were
fluent in Norwegian; and had either responded to and relapsed following or not responded to prior
ERP treatment, consisting of at least 6 sessions of ERP. Response to earlier ERP was defined by an at
least 35% reduction and a posttreatment Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of
15 or lower; relapse was defined by an at least 35% increase in Y-BOCS score from posttreatment, a
Y-BOCS score of 16 or more, and a Clinical Global Impression (CGI) improvement score of 6 (ie, “much
worse”) or higher.25 Nonresponders were defined as those with a reduction in Y-BOCS scores from
pretreatment to posttreatment of less than 35% and a Y-BOCS score of at least 16 after treatment. A
minimum of 4 weeks since treatment ended was required.
Exclusion Criteria
Patients who had ongoing substance abuse and/or dependence; had bipolar disorder or psychosis;
had active suicidal ideation or plans; had not receiving a stable dosage of antidepressants for at least
12 weeks or were not willing to receive a stable dosage during the 4 intervention days; were unwilling
to refrain from anxiety-reducing substances during the 2 days of exposure; had an intellectual
disability; and were living more than 1 hour by car or train from the treatment location were excluded.
Exclusion criteria related to the DCS were pregnancy or breastfeeding, kidney impairment,
hypersensitivity to DCS, porphyria, and epilepsy.
Determination of Eligibility
Trained assessors evaluated eligibility in terms of diagnosis, prior Y-BOCS scores, and the other
inclusion and exclusion criteria listed. Three senior investigators (G.K., B.H., J.A.H.) evaluated and
decided on questionable cases. However, this happened in only 1 case.
Adherence and Competence
All group sessions and therapist meetings were videotaped. Also, each group had a trained therapist
who observed and evaluated whether the group was conducted in accordance with the protocol.
No deviances from the protocol were reported for any of the groups. Two experts on concentrated
ERP who had not participated in the given group independently scored all videotapes for adherence
and competency using a 3-point scale. With 1 exception, both experts rated all groups as adherent
and competent.
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Independent Assessors
All Y-BOCS and Structured Clinical Interview for DSM-5 (SCID-5) were conducted by specially trained
and independent assessors and were audiotaped. A second assessor rated 20% of the taped
interviews. The obtained κ coefficient of diagnostic agreement was excellent (κ = 0.92). The same
procedure was used for the Y-BOCS interviews, and the interrater reliability of total score was
excellent (intraclass correlation coefficient, 0.94).
DCS
Each patient received 1 capsule of DCS (100 mg or 250 mg) or placebo each of the 2 days of
exposure. DCS and placebo were prepared in identical capsules by a research pharmacy. The
participants received written information about the medication and a phone number for questions
or to report adverse events. Some prior trials have indicated that DCS might potentiate negative
experiences when exposure is brief and not followed by a reduction in anxiety.26 To minimize this
risk, the first capsule was taken when the patient had gained experience with the procedure, ie, at
lunchtime on day 2.
At posttreatment, assessors were asked to guess which dosage of medication the patients had
received and also to indicate how certain they were of their guesses. The result showed no
correspondence between the actual group and guesses (χ 24 = 2.62; P = .62). Certainty was rated
from 0 to 10, and the mean (SD) score was 4.0 (3.0). Patients were asked the same questions and the
results showed a mean (SD) certainty of 0.3 (0.9), and no correspondence between the actual group
and their guesses (χ 24 = 2.45; P = .65).
Diagnostic Procedure
All patients were screened for inclusion using Y-BOCS and Mini International Neuropsychiatric
Interview (MINI).27 Patients receiving a preliminary OCD diagnosis after the MINI had a diagnostic
interview using the SCID-5.28 The SCID-5 was carried out by a team of masked independent assessors
who had undergone extensive training in the procedure.
Primary Outcome Measures
Patients were assessed pretreatment, posttreatment, and at 3-month and 12-month follow-ups. The
Y-BOCS29 was the primary outcome measure. In addition to mean scores on Y-BOCS, clinical
improvement was evaluated using a modified version (not including the CGI) of the international
consensus criteria, which defines response as a reduction of at least 35% of pretreatment Y-BOCS
score and remission as the response criterion plus a posttreatment Y-BOCS score of 12 points or
lower.25 Recovery was defined as in remission at 1-year follow-up. We also used the criteria by
Jacobson and Truax30 for clinically significant change; the results were very similar to those obtained
with the international consensus criteria (eTable in Supplement 2). Finally, we reported change in
diagnostic status (DSM-5) as assessed by SCID-5 at 3-month and 12-month follow-ups.
Secondary Outcome Measures
We used 6 self-report scales. They were the Dimensional Obsessive-Compulsive Scale Short Form,31
the Obsessive-Compulsive Inventory–Revised,32 Generalized Anxiety Disorder–7 (GAD-7),33 the
Patient Health Questionnaire–9 (PHQ-9),34 the Client Satisfaction Scale–8,35 and the Warwick-
Edinburgh Mental Well-being Scale (WEMWBS).36
Statistical Analysis
A meta-analysis37 found a moderate effect size for ERP with DCS for heterogeneous samples of
patients with OCD. Given the inclusion of only cognitive behavioral therapy nonresponders or
patients who had relapsed after ERP, we anticipated a larger effect size compared with previous ERP
studies. To have 80% power to detect a moderate effect size (d = 0.50) at an α of .05, a total of 160
patients needed to be included (64 in each of the DCS groups and 32 in the placebo group). We
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compared Y-BOCS scores between the placebo and DCS (100 mg and 250 mg) groups from
pretreatment to posttreatment and 2 follow-ups using mixed-effects regression models.37 The
dropout at the different points of assessment was very low (Figure). Following the principle of
intention to treat, all participants were included in the analyses, irrespective of missing data at any
measurement point.38 Time was treated as a categorical variable because we did not expect a strictly
linear effect of time. Between-group differences in Y-BOCS were assessed by including fixed effects
for treatment group, time, and the time × treatment group interaction. Bonferroni confidence
intervals were used for all analyses.
The mixed model included random intercepts for all participants. To take the potential
clustering effect of group leader into account, we also included a random effect for group leader.
Participants were also stratified according to use of antidepressants. To examine a possible effect of
current use of antidepressants, a 3-way interaction among time, treatment condition, and current
use of antidepressants was included in the analysis. Mixed models also allow the use of realistic
variance and correlation patterns to achieve more efficient statistical inference and, therefore,
greater statistical power.38 In this study, an unstructured covariance structure was used. This choice
was informed by comparing plausible covariance structures using goodness-of-fit statistics
(deviance, Akaike information criterion, and Bayesian information criterion).38 Intervention (within-
group) effect sizes were estimated using Glass Δ, with pretreatment SD as denominator. The
manipulation in intervention studies will often affect the SD as well as the mean; therefore Glass Δ is
recommended.39 Effect size is commonly interpreted as small (0.2), moderate (0.5), and large
(0.8).39
Data analysis was conducted from February to September 2019, using Stata version 16
(StataCorp) and SPSS statistical software version 25 (IBM Corp). Statistical significance was set at
P < .05, and all tests were 2-tailed.
Figure. Study Flowchart
220 Patients assessed for eligibility
57 Excluded
36 Did not meet inclusion criteria
20 Declined to participate
1 Lost contact after interview
163 Randomized
67 Randomized to receive
250 mg of D-cycloserine
65 Randomized to receive
250 mg of D-cycloserine
31 Randomized to receive
placebo
65 Assessed posttreatment 65 Assessed posttreatment 31 Assessed posttreatment
65 Assessed at 3-mo follow-up 64 Assessed at 3-mo follow-up 30 Assessed at 3-mo follow-up
57 Assessed at 12-mo follow-up 59 Assessed at 12-mo follow-up 30 Assessed at 12-mo follow-up
2 Not assessed
1 Withdrew after day 1
1 Unable to contact
1 Unable to contact 1 Unable to contact
9 Unable to contact 6 Unable to contact
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Results
Inclusion of Patients
The Figure presents the study flowchart. A total of 220 individuals were referred and assessed for
eligibility. Overall, 57 (25.9%) were excluded for reasons shown in the Figure. Of the 163 included
participants, 65 (39.9%) were randomized to receive 100 mg DCS, 67 (41.1%) to receive 250 mg DCS,
and 31 (19.0%) to receive placebo.
Pretreatment Characteristics
The total sample mean (SD) age was 34.5 (10.9) years, and most were women (117 [71.8%]). They had
experienced OCD for a mean (SD) of 16.2 (10.2) years. They had moderate to severe symptoms of
OCD and moderate symptoms of depression and generalized anxiety. A total of 100 (61.3%) had
relapsed following their previous treatment for OCD, whereas 63 (38.7%) did not respond to their
previous treatment. Overall, 72 (44.2%) received disability benefits, 56 (34.8%) were employed, and
33 (20.5%) were students. The total sample had attended school for a mean (SD) of 11.9 (3.9) years.
A total of 64 participants (39.3%) reported having family members who also had OCD symptoms.
Overall, 76 participants (46.6%) used psychotropic medication, of whom 52 (68.4%) used selective
serotonin reuptake inhibitors. A summary of sample characteristics is shown in Table 1. There were
no significant differences between the 3 groups except for mean (SD) previous pretreatment Y-BOCS
scores; participants in the 250 mg group had a 2-point lower mean score than participants in the
other 2 groups (DCS 250 mg group: 25.6 [4.8]; DCS 100 mg group: 27.7 [5.0]; placebo: 27.6 [5.1]).
The mean (SD) score on WEMWBS (39.7 [8.1]) indicated reduced mental well-being among the
participants (compared with normal population mean of 50). The mean (SD) score of 12.0 (5.9) on
Table 1. Pretreatment Characteristics of Participants by Treatment Group
Characteristic
Mean (SD)
250 mg (n = 67) 100 mg (n = 65) Placebo (n = 31)
Age, y 34.82 (11.75) 35.38 (11.42) 32.42 (7.06)
Women, No. (%) 45 (67.2) 49 (75.4) 23 (74.2)
Years in school 11.75 (3.82) 11.44 (4.13) 12.90 (3.26)
Age of OCD onset, y 19.21 (10.29) 19.12 (10.70) 16.79 (7.22)
Duration of OCD, y 15.89 (9.56) 16.58 (10.87) 15.93 (10.26)
Previous treatment exposure, h 26.17 (11.55) 26.37 (10.54) 27.97 (10.73)
Previous pretreatment Y-BOCS score 25.61 (4.79) 27.69 (5.00) 27.61 (5.07)
Previous posttreatment Y-BOCS score 14.51 (6.63) 13.52 (5.48) 14.69 (5.98)
Current Y-BOCS score 26.66 (3.99) 27.26 (3.75) 27.35 (3.83)
Any comorbid disorder, No. (%) 46 (68.7) 47 (72.3) 20 (64.5)
Comorbid disorders, No. 1.91 (2.05) 1.71 (1.88) 1.48 (1.55)
DOCS-SF score 26.55 (6.35) 27.82 (5.04) 27.20 (6.45)
OCI-R score 28.42 (11.09) 28.74 (13.32) 28.33 (10.91)
PHQ-9 score 11.40 (6.21) 12.75 (6.18) 11.43 (4.51)
GAD-7 score 12.31 (4.72) 12.84 (4.01) 11.56 (4.65)
WEMWBS score 37.79 (8.69) 39.14 (8.12) 40.63 (6.71)
Outcome of previous treatment, No. (%)
Nonresponder 29 (43.3) 23 (35.4) 11 (35.5)
Relapse 38 (56.7) 42 (64.6) 20 (64.5)
Self-reported OCD in the family, No. (%) 26 (38.8) 26 (40.0) 12 (38.7)
Employment, No. (%)
Work 22 (33.3) 25 (38.5) 9 (30.0)
Student 18 (27.3) 8 (12.3) 7 (23.3)
Disability 26 (39.4) 32 (49.2) 14 (46.7)
Psychotropic medication, No. (%) 25 (37.3) 36 (55.4) 15 (48.4)
Antidepressants, No. (%) 22 (32.8) 22 (33.8) 8 (25.8)
Abbreviations: DOCS-SF, Dimensional Obsessive-
Compulsive Scale–Short Form; GAD-7, Generalized
Anxiety Disorder–7; OCD, obsessive-compulsive
disorder; OCI-R, Obsessive-Compulsive
Inventory–Revised; PHQ-9, Patient Health
Questionnaire–9; WEMWBS, Warwick-Edinburgh
Mental Well-being Scale; Y-BOCS, Yale-Brown
Obsessive Compulsive Scale.
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the PHQ-9 and 12.4 (4.4) on the GAD-7 also indicated that the participants experienced moderate
symptoms of both depression and generalized anxiety. Most had comorbid diagnoses (113 [69.3%]),
with the most common being generalized anxiety disorder (52 [31.9%]) and major depressive
disorder (51 [31.3%]). The mean number of hours for the previous ERP treatment was 26.6 (SD, 11.0;
range, 9-60).
Number of Groups and Sites
There were a total of 36 groups with group sizes ranging from 3 to 6 patients. Nine clinics were
involved in the trial, of which 4 (Bergen, Oslo, Kristiansand, and Trondheim) treated 125 patients
(76.7%). There were no significant differences in Y-BOCS scores between the 4 clinics at the 4 points
of assessment.
Treatment Effect of DCS vs Placebo
Results on the primary and secondary outcome measures are presented in Table 2. To test the
hypothesis that DCS (regardless of dosage) enhances ERP, we specified a contrast that compared the
2 DCS groups (250 mg and 100 mg) with the placebo group and interacted this with time. This
interaction was not statistically significant (χ 23 = 6.23; P = .10). Treating the 2 DCS groups as
independent also resulted in a statistically nonsignificant time × treatment group interaction
(χ 26 = 7.59; P = .27). Effect sizes for the primary and secondary outcome measures are presented in
Table 3.
There was a significant main effect of time (χ 23 = 776.26; P < .001). The reduction in Y-BOCS
score from pretreatment to posttreatment was significant for all treatment groups (placebo, –13.29
[95% CI, –16.53 to –10.05]; 100 mg DCS, –15.40 [95% CI, –17.63 to –13.17]; 250 mg DCS, –14.57 [95%




time × groupPretreatment Posttreatment 3-mo Follow-up 12-mo Follow-up
Y-BOCS
250 mg DCS 26.66 (3.99) 12.09 (5.44) 13.03 (7.35) 14.63 (7.38)
.27100 mg DCS 27.26 (3.75) 11.86 (5.44) 13.77 (6.97) 14.19 (7.09)
Placebo 27.35 (3.83) 14.06 (7.13) 16.10 (7.23) 14.10 (7.57)
DOCS-SF
250 mg DCS 26.55 (6.35) 13.84 (7.28) 14.21 (7.97) 17.78 (8.55)
.61100 mg DCS 27.82 (5.04) 14.40 (7.54) 16.05 (8.91) 18.49 (9.61)
Placebo 27.20 (6.45) 16.27 (8.15) 18.25 (6.96) 19.38 (9.91)
OCI-R
250 mg DCS 28.42 (11.09) 10.26 (7.29) 11.70 (8.62) 18.14 (11.29)
.78100 mg DCS 28.74 (13.32) 12.75 (8.67) 14.75 (10.56) 20.10 (13.29)
Placebo 28.33 (10.91) 13.13 (11.65) 15.11 (9.77) 20.00 (12.86)
GAD-7
250 mg DCS 12.31 (4.72) 7.54 (5.83) 7.08 (4.93) 8.58 (5.09)
.006100 mg DCS 12.84 (4.01) 7.97 (4.27) 8.32 (4.70) 9.48 (5.04)
Placebo 11.56 (4.65) 7.97 (5.15) 10.29 (4.61) 10.92 (6.09)
PHQ-9
250 mg DCS 11.40 (6.21) 7.21 (6.01) 6.50 (5.44) 8.54 (5.88)
.45100 mg DCS 12.75 (6.18) 8.82 (6.37) 8.95 (6.25) 10.36 (6.31)
Placebo 11.43 (4.51) 7.70 (5.53) 8.54 (4.31) 10.31 (6.15)
WEMWBS
250 mg DCS 37.79 (8.69) NA NA 43.28 (8.82)
.97100 mg DCS 39.14 (8.12) NA NA 41.12 (9.57)
Placebo 40.63 (6.71) NA NA 44.15 (7.44)
Abbreviations: DCS, D-cycloserine; DOCS-SF,
Dimensional Obsessive-Compulsive Scale–Short Form;
GAD-7, Generalized Anxiety Disorder–7; NA, not
applicable; OCI-R, Obsessive-Compulsive Inventory–
Revised; PHQ-9, Patient Health Questionnaire–9;
WEMWBS, Warwick-Edinburgh Mental Well-being
Scale; Y-BOCS, Yale-Brown Obsessive
Compulsive Scale.
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CI, –16.80 to –12.34]). A statistically significant decrease in Y-BOCS at posttreatment was upheld at
both follow-up assessments for all treatment conditions (eFigure 2 in Supplement 2).
Specific comparisons at the primary end points (posttreatment and 12-month follow-up)
revealed no statistically significant differences on Y-BOCS score between the placebo group and the
2 DCS groups combined (posttreatment, χ 21 = 3.21; P = .07; 12-month follow-up, χ
2
1 = 0.07; P = .79).
Patients with a history of nonresponse increased their Y-BOCS scores from posttreatment to the
follow-up period (eFigure 3 in Supplement 2). The increase in Y-BOCS score from posttreatment to
3-month follow-up was statistically significant (2.43; 95% CI, 1.02 to 3.84), whereas the increase
from 3-month to 12-month follow-up was not (1.56; 95% CI, –0.12 to 3.26). Nonresponders also had
significantly higher Y-BOCS scores than those who had relapsed at posttreatment (2.34; 95% CI, 0.51
to 4.18), 3-month follow-up (3.89; 95% CI, 1.70 to 6.09), and 12-month follow-up (5.50; 95% CI, 3.26
to 7.73). To examine the effect of current use of antidepressants, a 3-way interaction between time,
treatment group, and current use of antidepressants was included in the analysis. A joint test of the
time × group × antidepressant interaction revealed no statistically significant interaction
(χ 26 = 1.22; P = .98).
There were no significant differences among conditions when using the international consensus
criteria at posttreatment (χ 24 = 3.35; P = .50) or 1-year follow-up (χ
2
4 = 4.73; P = .32), and there was
no significant difference with respect to diagnostic status among groups at the 3-month follow-up
(χ 22 = 1.38; P = .50) or 12-month follow-up (χ
2
2 = 0.24; P = .89) (Table 4).
There was a significant reduction in symptoms at 12 months, and within-group effect sizes
ranged from 3.01 (95% CI, 2.38-3.63) for the group receiving 250 mg DCS to 3.49 (95% CI, 2.78-4.18)
for the group receiving 100 mg DCS (all P < .001). However, there was no significant effect of
treatment group compared with placebo in obsessive-compulsive symptoms at posttreatment (250
Table 3. Within-Group and Between-Group Effect Sizes at Posttreatment and 12-Month Follow-Up
Outcome measure
Within-group effect sizea Between-group effect sizeb
Posttreatment 12-mo Follow-up Posttreatment 12-mo Follow-up
Glass Δ (95% CI) Glass Δ (95% CI) d (95% CI) d (95% CI)
Y-BOCS
250 mg DCS 3.65 (2.93 to 4.35) 3.01 (2.38 to 3.63) 0.33 (–0.10 to 0.76) –0.07 (–0.51 to 0.37)
100 mg DCS 4.11 (3.31 to 4.89) 3.49 (2.78 to 4.18) 0.36 (–0.08 to 0.79) –0.01 (–0.45 to 0.42)
Placebo 3.47 (2.45 to 4.46) 3.46 (2.45 to 4.45) NA NA
DOCS-SF
250 mg DCS 2.00 (1.51 to 2.48) 1.38 (0.95 to 1.80) 0.32 (–0.12 to 0.76) 0.18 (–0.28 to 0.64)
100 mg DCS 2.66 (2.08 to 3.23) 1.85 (1.37 to 2.32) 0.24 (–0.19 to 0.67) 0.09 (–0.37 to 0.55)
Placebo 1.69 (1.02 to 2.35) 1.21 (0.59 to 1.81) NA NA
OCI-R
250 mg DCS 1.64 (1.18 to 2.09) 0.93 (0.54 to 1.31) 0.32 (–0.12 to 0.76) 0.19 (–0.30 to 0.62)
100 mg DCS 1.20 (0.79 to 1.60) 0.65 (0.28 to 1.01) 0.04 (–0.39 to 0.47) –0.01 (–0.47 to 0.45)
Placebo 1.39 (0.77 to 2.00) 0.76 (0.20 to 1.32) NA NA
GAD-7
250 mg DCS 1.01 (0.62 to 1.40) 0.79 (0.41 to 1.17) 0.08 (–0.36 to 0.51) 0.43 (–0.03 to 0.90)
100 mg DCS 1.21 (0.80 to 1.62) 0.84 (0.45 to 1.22) 0.00 (–0.43 to 0.43) 0.27 (–0.19 to 0.73)
Placebo 0.77 (0.20 to 1.33) 0.14 (–0.41 to 0.67) NA NA
PHQ-9
250 mg DCS 0.67 (0.31 to 1.04) 0.46 (0.10 to 0.82) 0.08 (–0.35 to 0.52) 0.30 (–0.17 to 0.76)
100 mg DCS 0.64 (0.27 to 1.00) 0.39 (0.03 to 0.74) –0.18 (–0.62 to 0.25) –0.01 (–0.47 to 0.45)
Placebo 0.83 (0.27 to 1.37) 0.25 (–0.28 to 0.78) NA NA
WEMWBS
250 mg DCS NA 0.40 (–0.79 to –0.01) NA 0.10 (–0.42 to 0.63)
100 mg DCS NA 0.24 (–0.61 to 0.13) NA 0.34 (–0.19 to 0.86)
Placebo NA 0.52 (–1.10 to 0.06) NA NA
Abbreviations: DCS, D-cycloserine; DOCS-SF,
Dimensional Obsessive-Compulsive Scale–Short Form;
GAD-7, Generalized Anxiety Disorder–7; NA, not
applicable; OCI-R, Obsessive-Compulsive Inventory–
Revised; PHQ-9, Patient Health Questionnaire–9;
WEMWBS, the Warwick-Edinburgh Mental Well-being
Scale; Y-BOCS, Yale-Brown Obsessive
Compulsive Scale.
a Glass Δ was calculated by subtracting the mean
posttreatment (or follow-up) score from the
pretreatment score and dividing the result with the
pretreatment SD.
b Effect sizes (Cohen d) for between-group differences
were calculated using the placebo group as a
comparison group.
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mg group: d = 0.33; 95% CI, −0.10 to 0.76; 100 mg group: d = 0.36; 95% CI, −0.08 to 0.79) and
symptoms of depression and anxiety at the 12-month follow-up (eg, PHQ-9 score among 250 mg
group: d = 0.30; 95% CI, −0.17 to 0.76; GAD-7 score among 100 mg group: d = 0.27; 95% CI, −0.19
to 0.73) (Table 3). There were also signs of improvement in well-being at the 12-month follow-up
(250 mg group: d = 0.10; 95% CI, −0.42 to 0.63; 100 mg group: d = 0.34; 95% CI, −0.19 to 0.86). For
all outcome measures, there were no significant time × group effects, except for generalized anxiety.
The reduction in GAD-7 from pretreatment to posttreatment was significant for all treatment groups
(placebo, –3.69 [95% CI, –5.99 to –1.38]; 100 mg DCS, –4.86 [95% CI, –6.39 to –3.32]; 250 mg DCS,
–4.78 [95% CI, –6.32 to –3.23]). Unlike the 2 DCS groups, the GAD-7 score in the placebo group
significantly increased from posttreatment to the 3-month follow-up (2.30; 95% CI, 0.14 to 4.47). At
the 3-month follow-up, the mean GAD-7 score for the placebo group was also significantly higher
than that of the 250 mg DCS group (mean difference, 3.11; 95% CI, 0.53 to 5.67) but not that of the
100 mg DCS group. There were no statistically significant differences between the groups at the
12-month follow-up.
Client Satisfaction and Adverse Events
Participants were generally satisfied with the treatment as indicated by a mean score of 28.9 (SD,
3.63; median, 30; range 11-32) on the Client Satisfaction Questionnaire–835 (maximum score is 32). A
total of 25 patients reported 28 adverse events, as follows: headaches (9 [36.0%]), diarrhea (5
[20.0%]), constipation (1 [4.0%]), tiredness (2 [8.0%]), dizziness (1 [4.0%]), vomiting (2 [8.0%]),
and pain (1 [4.0%]). The adverse effects were not systematically related to whether the patients had
received DCS or placebo (9 patients [36.0%] from the 250 mg group, 10 [40.0%] from the 100 mg
group, and 6 [24.0%] from the placebo group). No serious adverse effects were reported.
Table 4. Clinical Improvement According to the International Consensus Criteria and
Change in Diagnostic Status
Outcome
Group, No. (%)
DCS 250 mg DCS 100 mg Placebo Total
Clinical improvement
Posttreatment
Remission 39 (60.0) 35 (53.8) 17 (54.8) 91 (56.5)
Response 15 (23.1) 22 (33.8) 7 (22.6) 44 (27.3)
No change 11 (16.9) 8 (12.4) 7 (22.6) 26 (16.2)
Total No. 65 65 31 161
12-mo Follow-up
Remission 31 (50.8) 27 (47.4) 12 (42.9) 70 (47.9)
Response 10 (16.4) 7 (12.3) 5 (17.9) 22 (15.1)
No change 20 (32.8) 23 (40.3) 11 (39.2) 54 (37.0)
Total No. 61 57 28 146
Diagnostic status
3-mo Follow-up
OCD 27 (41.5) 27 (41.5) 16 (53.3) 90 (56.3)
No OCD 38 (58.5) 38 (58.5) 14 (46.7) 70 (43.8)
Total No. 65 65 30 160
12-mo Follow-up
OCD 27 (47.4) 27 (45.8) 13 (41.9) 67 (45.6)
No OCD 30 (52.6) 32 (54.2) 18 (58.1) 80 (54.4)
Total No. 57 59 31 147
Abbreviations: DCS, D-cycloserine; OCD, obsessive-
compulsive disorder.
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Discussion
To our knowledge, this project represents the largest study testing a possible potentiation effect of
DCS on ERP treatment for patients with OCD. While most previous DCS studies have included
samples in which most participants can expect a clinical response to ERP treatment alone, the target
group in the current study was patients with difficult-to-treat OCD, defined as patients who recently
had received ERP and either not responded or responded and then relapsed. Thus, if DCS has a
potentiating effect on ERP treatment, it could be expected to be detected in this group of patients.
Also, this group of patients represented those who would be the most in need of a potentiation of the
psychological treatment. The results showed that there was no indication that DCS potentiated the
treatment response, neither at posttreatment nor at 1-year follow-up. Also, opposed to the study by
Anderson et al,17 we did not find any significant effect of ongoing treatment with antidepressants
on the effect of DCS.
Limitations
This study has limitations. The lack of a DCS effect in the current study was not due to an overall
inferior effect of the ERP treatment. Compared with means across 5 previous randomized clinical
trials8,9,14,16,24 on ERP and DCS in patients with OCD, the present sample of patients with difficult-to-
treat OCD started treatment with somewhat higher Y-BOCS scores (27.0 vs 25.9) but ended
treatment at a very similar mean (12.5 vs 12.3). Furthermore, the posttreatment response rate of 135
patients (83.9%; ie, 91 patients who achieve remission and 44 patients with at treatment response)
and remission rate of 56.5% (91 patients) compares favorably with rates reported in meta-analyses4
(response rate of 65.0% and remission rate of 50.0% for 15 samples).
In contrast to previous studies, the maskedness of the assessors was tested in the current study;
their guesses of which treatment each patient had received was random. It is also noteworthy that
only 1 patient dropped out of therapy and only 1 other did not complete the posttreatment
assessment. Thus, selective attrition was not a problem in this study. Furthermore, the sample
primarily consisted of women. Also, there was a slight difference between groups in pretreatment Y-
BOCS scores.
The nonsignificant findings correspond with previous findings.10,11,14-16 The study was powered
to detect an effect size of 0.50 because a smaller effect size would have limited clinical significance.
This is especially the case given that the targeted group was patients with difficult-to-treat OCD. A
2019 meta-analysis40 suggested that more DCS doses (up to 9) and administering DCS more than 60
minutes before exposure were associated with better outcomes. However, the concentrated format
used in the present study is not compatible with administering more than 2 doses. Previous research
has also indicated that a possible effect occurs during treatment or immediately after treatment.8,9,18
Given our concentrated treatment format and having the first follow-up visit after 3 months, the
theory of accelerated improvement was not tested. Given the nonsignificant results, we suggest that
future research should test the suggestions brought forth by Rosenfield et al.40
Conclusions
In this randomized clinical trial, DCS did not potentiate the effect of concentrated ERP for patients
with difficult-to-treat OCD. However, concentrated ERP treatment was associated with improvement
in symptoms of OCD, anxiety, and depression.
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